CliffBio
biologic

Vivotif

Typhoid Vaccine Live Oral Ty21a

Loss of exclusivityDecember 2001projected — 12-year biologic exclusivity estimate
CompanyBavarian Nordic A/S

Drug detail

Brand nameVivotif
Active ingredientTyphoid Vaccine Live Oral Ty21a
Strength2-6.8 BIL. CFU
Dosage formCapsule
RouteOral
ModalityBiologic
FDA approvalDecember 1989
Marketing statusRx

More from Bavarian Nordic A/S

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Vivotif patent cliff — loss of exclusivity December 2001 | CliffBio